Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population-matched analysis

Leukemia

Volumn 19, Issue 6, 2005, Pages 1029-1033

  Dreger, Peter ^a,b,aa   Brand, R ^c   Milligan, D ^d   Corradini, P ^e   Finke, J ^f   Lambertenghi Deliliers, G ^g   Martino, R ^h   Russell, N ⁱ   van Biezen, A ^c   Michallet, M ^j   Niederwieser, D ^k   Herrmann, R P ^l   Greinix, H ^m   Ferrant, A ⁿ   Koza, V ^o   Vitek, A ^p   Vindelov L ^q   Ruutu, T ^r   Remes, K ^s   Milpied, N ^t   Varet, B ^u   Gorin, N C ^v   Sutton, L ^w   Kroger N ^x   Hertenstein, B ^y   Trumper L ^z   Beelen, D ^z   Derigs, G ^ab   Casper, J ^ac   Stilgenbauer, S ^ad   Bunjes, D ^ad   Majolino, I ^ae   Bacigalupo, A ^af   Meloni, G ^ag   Willemze, R ^c   de Witte, T ^ah   Cornelissen, J J ^ai   Verdonck, L ^aj   Hansz, J ^ak   Morgenstern, G ^al   Hows, J ^m   Goldstone, A ^am   Aschan, J ^an   Oberg G ^ao   Esteve, J ^ap   Caballero, D ^aq   Iriondo, A ^ar   more..

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF FREIBURG   (Germany)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k UNIVERSITY OF LEIPZIG   (Germany)

^l ROYAL PERTH HOSPITAL   (Australia)

^m Clinique Universitaire St Luc ^*  (United Kingdom)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^o CHARLES UNIVERSITY   (Czech Republic)

^p INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^q Rigshospitalet   (Denmark)

^r HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^s TURKU UNIVERSITY HOSPITAL   (Finland)

^t CHU DE NANTES   (France)

^u HÔPITAL NECKER ENFANTS MALADES   (France)

^v HÔPITAL SAINT ANTOINE   (France)

^w PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^x UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^y HANNOVER MEDICAL SCHOOL   (Germany)

^z SAARLAND UNIVERSITY   (Germany)

^aa UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^ab UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^ac UNIVERSITY OF ROSTOCK   (Germany)

^ad UNIVERSITY HOSPITAL ULM   (Germany)

^ae VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^af UNIVERSITY OF GENOA   (Italy)

^ag SAPIENZA UNIVERSITY OF ROME   (Italy)

^ah RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai ERASMUS MEDICAL CENTER   (Netherlands)

^aj UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ak POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^al CHRISTIE HOSPITAL   (United Kingdom)

^am South East Environmental Business Association   (United Kingdom)

^an KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ao UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^ap HOSPITAL CLÍNIC   (Spain)

^aq NONE   (Spain)

^ar HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

Allogeneic stem cell transplantation; CLL; Reduced intensity conditioning; Treatment related mortality

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THIOTEPA;

ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONBIOLOGICAL MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK REDUCTION; SEX; SIDE EFFECT; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGISTER; RISK FACTOR;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 20844436596     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403745     Document Type: Article

References (19)

1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
3. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
4. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
5. Khouri IF, Przepiorka D, van BK, O'Brien S, Palmer JL, Lerner S et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466-473.
6. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717-722.
7. Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15: 445-451.
8. Doney KC, Chauncey T, Appelbaum FR. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 2002; 29: 817-823.
9. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-992.
10. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
11. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28-35.
12. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Low treatment-related mortality but retained graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using reduced-intensity conditioning. Leukemia 2003; 17: 841-848.
13. Faulkner RD, Craddock C, Byrne IL, Mahendra P, Haynes AP, Prentice HG et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428-434.
14. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
15. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, De Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
16. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602.
17. Böttcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637-1645.
18. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
19. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post-grafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.